Ecosystem
Beta Site
Search Results
251 items found for "drug repurposing"
- Metallo-protease Peptidase M84 from Bacillusaltitudinis induces ROS-dependent apoptosis in ovarian cancer cells by targeting PAR-1
This established Peptidase M84 as a drug candidate for receptor mediated targeted-therapy of ovarian Industry News Adhesion GPCRs GPCR Events, Meetings, and Webinars Reviews, GPCRs, and more GPCR Binders, Drugs
- GPCRs and fibroblast heterogeneity in fibroblast-associated diseases
About one-third of the commercially available drugs for various diseases target the GPCRs. Industry News Adhesion GPCRs GPCR Events, Meetings, and Webinars Reviews, GPCRs, and more GPCR Binders, Drugs
- Ep 95 with Chris Langmead
He is an acknowledged expert in drug discovery, particularly in the field of psychiatry, where he has He has published over 70 research articles, reviews and book chapters on drug discovery, which have been
- About Us | Dr. GPCR Ecosystem
GPCR Ecosystem We bring the GPCR community to fuel GPCR drug discovery one receptor at a time. The goal is to increase understanding of GPCR function and discover better drugs together.
- Biochemical pharmacology of adenylyl cyclases in cancer
Understanding the signaling pathways involved in cancer progression is essential for the discovery of new drug Industry News Adhesion GPCRs GPCR Events, Meetings, and Webinars Reviews, GPCRs, and more GPCR Binders, Drugs
- CaaX-motif-adjacent residues influence G protein gamma (Gγ) prenylation under suboptimal conditions
Our results may also provide molecular reasoning for repurposing statins as Ras oncogene inhibitors and Industry News Adhesion GPCRs GPCR Events, Meetings, and Webinars Reviews, GPCRs, and more GPCR Binders, Drugs
- Pan-cancer functional analysis of somatic mutations in G protein-coupled receptors
date December 1, 2022 Abstract G Protein-coupled receptors (GPCRs) are the most frequently exploited drug Industry News Adhesion GPCRs GPCR Events, Meetings, and Webinars Reviews, GPCRs, and more GPCR Binders, Drugs
- Distinct sub-cellular signal propagation as a component of functional selectivity
cell signaling and GPCRs and made seminal contributions to our understanding of this major class of drug energy transfer (BRET) resulted in the development of screening assays that are now widely used for drug
- Interaction with the cell adhesion molecule NEGR1 affects mGluR5 cell signalling
the study of the mechanisms involved in neurodegeneration and the characterization of neuroprotective drugs These drugs were shown to be very effective to rescue the cell death observed in a mouse model of Huntington
- Structural Basis for the Recognition of GPRC5D by Talquetamab, a Bispecific Antibody for Multiple Myeloma
Talquetamab, a Food and Drug Administration-approved T-cell-directing bispecific antibody developed for Industry News Adhesion GPCRs GPCR Events, Meetings, and Webinars Reviews, GPCRs, and more GPCR Binders, Drugs
- In Silico Design of Novel RGS2-Galpha-q Interaction Inhibitors with Anticancer Activity
We sought to develop RGS2 inhibitors as potential chemotherapeutic agents utilizing structure-based drug Industry News Adhesion GPCRs GPCR Events, Meetings, and Webinars Reviews, GPCRs, and more GPCR Binders, Drugs
- Identification of Small-Molecule Antagonists Targeting the Growth Hormone Releasing Hormone Receptor (GHRHR)
The GHRHR has recently been highlighted as a promising drug target toward several types of cancer and Industry News Adhesion GPCRs GPCR Events, Meetings, and Webinars Reviews, GPCRs, and more GPCR Binders, Drugs
- The GPCR-Gαs-PKA signaling axis promotes T cell dysfunction and cancer immunotherapy failure
G-protein-coupled receptors (GPCRs) are the most intensively studied drug targets but are underexplored Industry News Adhesion GPCRs GPCR Events, Meetings, and Webinars Reviews, GPCRs, and more GPCR Binders, Drugs
- LP2, a cyclic angiotensin-(1-7) analog extended with an N-terminal D-lysine, impairs growth of patient-derived xenografts of colorectal carcinoma in mice
, the extremely low dose of LP2 at which antitumor activity is exerted, the synergism with selected drugs Industry News Adhesion GPCRs GPCR Events, Meetings, and Webinars Reviews, GPCRs, and more GPCR Binders, Drugs
- Ep 29 with Eleonora Comeo
Eleonora Comeo About this episode Eleonora Comeo is a doctoral candidate in Medicinal Chemistry and Drug
- A GPCR checkpoint drives CD8+ T cell dysfunction and immunotherapy failure in mice
Industry News Adhesion GPCRs GPCR Events, Meetings, and Webinars Reviews, GPCRs, and more GPCR Binders, Drugs
- Comparative Analysis of the GNAI Family Genes in Glioblastoma through Transcriptomics and Single-Cell Technologies
treatment of GBM is challenging due to the presence of the blood-brain barrier (BBB), which hinders drug Industry News Adhesion GPCRs GPCR Events, Meetings, and Webinars Reviews, GPCRs, and more GPCR Binders, Drugs
- Ep 36 with Dr. Michel Bouvier
cell signaling and GPCRs and made seminal contributions to our understanding of this major class of drug energy transfer (BRET) resulted in the development of screening assays that are now widely used for drug
- Ep 00 with Dr. Yamina Berchiche
opportunities to connect, share, form trusting partnerships, grow, and thrive together to accelerate GPCR drug
- Ep 97 with Robert Laprairie
Robert Laprairie is an Associate Professor and the Saskatchewan Research Chair in Drug Discovery and
- Ep 148 with Dr Arthur Christopoulos
His research focuses on novel paradigms of drug action at GPCRs, particularly allosteric modulation and 2021 he was elected a Fellow of the Australian Academy of Science for his seminal contributions to drug significance of translating fundamental discoveries into clinical applications, the potential of new drugs Postdoctoral Position, Scientific Dynamics, and New Drug Targets Arthur shared his decision to undertake Lastly, they discussed the progress of new drugs targeting specific receptors for various diseases, with
- Ep 149 with Dr Arthur Christopoulos
His research focuses on novel paradigms of drug action at GPCRs, particularly allosteric modulation and 2021 he was elected a Fellow of the Australian Academy of Science for his seminal contributions to drug significance of translating fundamental discoveries into clinical applications, the potential of new drugs Postdoctoral Position, Scientific Dynamics, and New Drug Targets Arthur shared his decision to undertake Lastly, they discussed the progress of new drugs targeting specific receptors for various diseases, with
- Ep 156 with Dr. Justin English
GPCR Podcast << Back to podcast list Empowering Drug Discovery for the GPCR Community with Dr.
- Ep 44 with Dr. Steven Foord
He also discovered and championed a novel prostaglandin EP4 drug candidate for development.
- Ep 91 with Dr. Oliver Hartley
Oliver Hartley Oliver Hartley is VP for Drug Discovery at Orion Biotechnology .
- Activation of PI3K/Akt pathway by G protein-coupled receptor 37 promotes resistance to cisplatin-induced apoptosis in non-small cell lung cancer
Most importantly, we investigated whether GPR37 affects cisplatin-induced drug resistance in NSCLC. Industry News Adhesion GPCRs GPCR Events, Meetings, and Webinars Reviews, GPCRs, and more GPCR Binders, Drugs
- Ep 76 with Steve McCloskey
Scientists and Engineers working at the nanoscale, specifically protein engineering and small molecule drug
- Comparison of infectious complications with BCMA-directed therapies in multiple myeloma
BCMA-targeted chimeric-antigen-receptor T-cell therapy (CAR-T), bispecific-antibodies (BsAb) and antibody-drug-conjugates Industry News Adhesion GPCRs GPCR Events, Meetings, and Webinars Reviews, GPCRs, and more GPCR Binders, Drugs
